Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw their risk of disease recurrence cut by nearly half over five years, according to extended follow-up data from the KEYNOTE-942 trial. The randomized phase 2b study compared individualized neoantigen therapy mRNA-4157, also known as V940, combined with pembrolizumab against pembrolizumab alone in patients whose tumors had been surgically removed. The result represents one of the longest efficacy signals ever recorded for a personalized cancer vaccine and raises direct questions about how quickly this combination could reach routine clinical use.
Why five-year melanoma vaccine data changes the treatment calculus
Standard adjuvant immunotherapy with checkpoint inhibitors like pembrolizumab has improved outcomes for melanoma patients after surgery, but a significant share of those with stage III or IV disease still experience recurrence within several years. The KEYNOTE-942 trial was designed to test whether adding a vaccine tailored to each patient’s unique tumor mutations could extend the benefit beyond what pembrolizumab delivers on its own. The trial’s formal entry on ClinicalTrials.gov lists recurrence-free survival and distant metastasis-free survival as its primary and key secondary endpoints, underscoring the focus on long-term control of micrometastatic disease.
A nearly 50 percent reduction in recurrence risk at five years carries weight because late relapses in melanoma often involve resistant tumor clones that evade the original immune response. If the vaccine’s benefit holds at this duration, it suggests the immune system may be learning to recognize and destroy tumor cells carrying patient-specific mutations well beyond the initial treatment window. That kind of durable immune memory has been the central promise of personalized cancer vaccines, and this trial offers one of the first extended datasets to support it in a randomized setting.
One hypothesis worth tracking as more data emerge is whether the recurrence-free survival advantage at five years correlates with a measurable decline in circulating tumor DNA carrying resistant mutations. If such a molecular signal were validated, it could serve as an early surrogate endpoint, allowing future phase 3 trials to reach conclusions more quickly. At present, however, no published data from KEYNOTE-942 have confirmed that link, and regulators continue to rely on traditional time-to-event endpoints for pivotal decisions.
KEYNOTE-942 trial design and the peer-reviewed record
The study randomized participants with resected high-risk melanoma to receive either the individualized neoantigen therapy mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy. Each patient’s vaccine was manufactured to target up to 34 neoantigens identified from sequencing of their own tumor DNA and matched normal tissue. The trial’s design, dosing schedule, and statistical analysis plan were documented in the registry before unblinding, and a version history within the public trial documentation indicates that endpoint definitions and analysis timing were prespecified rather than adjusted after early results.
The earlier follow-up from KEYNOTE-942 has been published in a randomized phase 2b report in The Lancet, which detailed baseline characteristics, recurrence-free survival methodology, and the safety profile of the combination regimen. In that analysis, the recurrence-free survival curves separated in favor of the vaccine-plus-pembrolizumab arm, with a hazard ratio indicating a clinically meaningful reduction in risk of recurrence or death. The five-year update, while not yet fully captured in a new peer-reviewed manuscript, extends that signal and suggests the benefit is not merely an early transient effect.
Moderna developed mRNA-4157 using the same lipid nanoparticle delivery platform that underpins its COVID-19 vaccine, while Merck contributed pembrolizumab, marketed as Keytruda, as the immunotherapy backbone. The collaboration allowed rapid design and manufacture of individualized vaccines based on each patient’s mutational landscape. Patients in the combination arm received multiple vaccine doses alongside standard pembrolizumab infusions, and the control arm followed the same pembrolizumab schedule without the personalized component. Although the extended follow-up has been highlighted in company communications, exact five-year hazard ratios and updated Kaplan-Meier estimates have not yet been incorporated into the primary registry entry or a new journal article.
What the five-year data still cannot answer
Several gaps remain in the public record even as enthusiasm grows around the five-year findings. The precise hazard ratio and confidence intervals for recurrence-free survival at the five-year mark have not been published in a peer-reviewed venue or updated in the registry as of the latest available records. Without those numbers, independent statisticians cannot rigorously assess the robustness of the benefit, explore whether the proportional hazards assumption holds over time, or determine whether the effect is consistent across subgroups defined by stage, PD-L1 expression, or tumor mutation burden.
Similarly, the distribution of benefit across different types of high-risk melanoma remains unclear. The Lancet publication summarized outcomes by stage and certain clinical features, but more granular analyses-such as performance in patients with very high mutational loads, or in those with specific driver mutations-have not been fully disclosed. For clinicians deciding which patients might benefit most from a resource-intensive personalized vaccine, such subgroup data will be essential.
Patient-reported quality-of-life outcomes and detailed toxicity information specific to the extended follow-up window are also absent from the formal sources. The initial study report covered adverse events during the treatment period, noting immune-related toxicities consistent with pembrolizumab and additional low-grade events potentially attributable to the vaccine. However, long-term side effects, late immune-related events, and any impact on functional status several years after therapy have not yet appeared in the public dataset. For patients weighing an aggressive adjuvant strategy, long-term tolerability is as important as recurrence-free survival.
Manufacturing logistics present another open question. Each mRNA-4157 dose is built from scratch based on a patient’s tumor sequencing results, which requires coordination among surgical teams, pathology labs, sequencing facilities, and manufacturing sites. The turnaround time from biopsy to first vaccine dose, the proportion of patients for whom adequate neoantigens can be identified, and the rate of manufacturing failures or delays are not detailed in the registry or the published paper. If the combination advances to phase 3 and eventually routine practice, those operational variables will directly influence which centers can offer the therapy and how quickly it can be started after surgery.
Cost and access considerations follow naturally from the manufacturing complexity. Personalized vaccines require individualized design, which is inherently more expensive than off-the-shelf biologics. While no formal cost-effectiveness analyses have yet been published for mRNA-4157 plus pembrolizumab, payers will eventually need to weigh the upfront investment against potential savings from avoided recurrences, hospitalizations, and subsequent lines of therapy. In health systems with constrained budgets, even a strong efficacy signal may not translate into broad access without supportive economic data.
Implications for future trials and clinical practice
The durability of benefit observed in KEYNOTE-942 is likely to accelerate the design of larger confirmatory trials. A phase 3 study in high-risk melanoma would be expected to use recurrence-free survival as a primary endpoint, with overall survival as a key secondary measure and prespecified subgroup analyses to clarify which patients derive the most benefit. Depending on regulatory feedback, investigators may also explore adaptive designs that incorporate early molecular readouts, such as circulating tumor DNA, as supportive evidence.
Beyond melanoma, the five-year data strengthen the broader case for individualized neoantigen vaccines as a platform technology. If similar approaches demonstrate durable benefit in other solid tumors with high mutational burdens, such as certain lung and bladder cancers, the field could see a shift toward bespoke adjuvant regimens layered onto existing checkpoint inhibitors. However, each tumor type will bring its own biological challenges, and the positive experience in melanoma cannot simply be extrapolated without rigorous testing.
For now, the KEYNOTE-942 results offer a cautiously optimistic glimpse of what personalized cancer vaccination might achieve when paired with established immunotherapy. The nearly halved recurrence risk at five years suggests that the immune system can be trained to mount a long-lasting, mutation-specific response capable of suppressing or eliminating residual disease. Yet until full five-year data are published with detailed statistics, safety outcomes, and operational metrics, clinicians and patients will have to balance the promise of durable benefit against the uncertainties that still surround this first generation of individualized mRNA cancer vaccines.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
